Meitav Investment House’s Galmed Pharmaceuticals GLMD Stock Holding History

Meitav Investment House’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3,551	Closed	-$4.69M	–	456
2019 Q2	$4.69M	Sell	3,551 -80	-2%	-$103K	0.31%	54
2019 Q1	$5.34M	Hold	3,631	–	–	0.3%	56
2018 Q4	$4.46M	Sell	3,631 -2	-0.1%	-$3.49K	0.28%	65
2018 Q3	$8.95M	Buy	3,633 +987	+37%	+$2.31M	0.44%	58
2018 Q2	$2.99M	Hold	2,646	–	–	0.13%	98
2018 Q1	$2.65M	Hold	2,646	–	–	0.14%	80
2017 Q4	$4.36M	Buy	+2,646	New	+$3.91M	0.25%	73

Other funds holding GLMD

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FMBTD

First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Meitav Investment House's GLMD Position: Q3 2019 in Review

Meitav Investment House sold out of Galmed Pharmaceuticals (GLMD) in Q3 2019, closing a stake of 3,551 shares — an estimated $4.69M sold.

Meitav Investment House first reported a position in GLMD in Q4 2017 and held it in 7 quarters. The position peaked at $8.95M in Q3 2018. 31 funds tracked by Wall St. Rank hold GLMD as of Q3 2019.

Meitav Investment House reported no remaining Galmed Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Meitav Investment House sold 3,551 Galmed Pharmaceuticals shares in Q3 2019, an estimated $4.69M.
Meitav Investment House first reported a position in Galmed Pharmaceuticals in Q4 2017 and held it in 7 quarters.
Meitav Investment House's Galmed Pharmaceuticals position peaked at $8.95M in Q3 2018.
31 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2019.

Based on Meitav Investment House's 13F filing for Q3 2019, filed 14 Nov 2019.